AstraZeneca lupus drug impresses in mid-stage trial

LONDON (Reuters) - AstraZeneca's experimental lupus drug anifrolumab significantly cut disease activity in a mid-stage clinical trial, boosting hopes for a medicine the company believes could become a $1 billion-a-year seller.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news